> Pozen of Chapel Hill, NC, has received approval from UK regulators for MT 100, a migraine drug. It's the first regulatory approval received by the drug developer. Report
> The UK's Genosis has raised ₤7 million through a stock placement. Report
> Japan's Eisai has transferred sales rights to the antibiotic Rulid to Sanofi-Aventis. Report
And Finally… International Congress Biotechnology 2005 in Havana is touting Cuba's work in the biotech field. Report